AXL Kinase Inhibitor Pipeline Market Report 2022: Insights on 15+ Companies and 15+ Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “AXL Kinase Inhibitor – Pipeline Insight, 2022” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “AXL Kinase Inhibitor – Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in AXL Kinase Inhibitor pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

AXL Kinase Inhibitor: Overview

AXL receptor tyrosine Kinase is a member of the tyrosine-protein Kinase receptor Tyro3, Axl and proto-oncogene tyrosine-protein Kinase Mer family of receptor tyrosine Kinases. AXL is a member of a complex signaling network that is involved in the control of cell proliferation and differentiation. AXL is widely expressed in healthy tissues, where it plays a variety of roles, including clearing apoptotic material, regulating cell survival, maintaining vascular integrity, and hematopoiesis.

AXL has emerged as a novel biomarker due to its role in biological processes and tumorigenesis. Because of the pleiotropic role of AXL in tumor pathophysiology and drug resistance, AXL represents a promising therapeutic target in the management of cancer. AXL inhibitors have been shown to potentiate tumor cell apoptosis and suppress migration and invasion. Targeting AXL enhances the therapeutic efficacy of chemotherapy and other small-molecule inhibitors, such as VEGF, EGFR, PI3K, PARP, and HER2 inhibitors.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence AXL Kinase Inhibitor R&D. The therapies under development are focused on novel approaches for AXL Kinase Inhibitor.

AXL Kinase Inhibitor Emerging Drugs Chapters

This segment of the AXL Kinase Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

AXL Kinase Inhibitor Emerging Drugs

Bemcentinib: BerGenBio / Rigel Pharmaceuticals

Bemcentinib (BGB324) is a potent, selective and orally bioavailable AXL inhibitor and a potential future cornerstone to therapy for aggressive diseases, including immune-evasive, therapy resistant cancers, fibrosis and viral infection. The drug is in phase II program, focused on establishing proof of concept that bemcentinib may reverse and prevent resistance to immune, targeted and chemotherapy.

Sitravatinib: Mirati Therapeutics

Sitravatinib is an oral, potent, spectrum-selective RTK inhibitor. It inhibits several closely related RTKs, including the TAM family (TYRO3, AXL and MER), VEGFR2 and KIT. This inhibition weakens the cancer’s defenses in the tumor microenvironment.

AXL Kinase Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different AXL Kinase Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on AXL Kinase Inhibitor

There are approx. 15+ key companies which are developing the AXL Kinase Inhibitor. The companies which have their AXL Kinase Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Mirati Therapeutics.

Key Players

• BerGenBio
• Rigel Pharmaceuticals
• Mirati Therapeutics
• Ipsen
• SignalChem Lifesciences
• Arcus Biosciences
• Symphogen
• Qurient Co
• Daiichi Sankyo Company
• Aravive
• Exelixis

Key Products

• Bemcentinib
• Sitravatinib
• Cabozantinib

Research Programme: TAM inhibitors

Research Programme: AXL receptor tyrosine kinase inhibitors

• Sym 028
• Q-702
• AB 329
• Aravive S6
• XL092

Key Topics Covered:

Introduction

Executive Summary

AXL Kinase Inhibitor: Overview

• Structure
• Mechanism of Action

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

AXL Kinase Inhibitor – Analytical Perspective

In-depth Commercial Assessment

• AXL Kinase Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends

AXL Kinase Inhibitor Collaboration Deals

• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

• Comparative Analysis

Sitravatinib: Mirati Therapeutics

• Product Description
• Research and Development
• Product Development Activities

Mid Stage Products (Phase II)

• Comparative Analysis

Bemcentinib: BerGenBio/Rigel Pharmaceuticals

• Product Description
• Research and Development
• Product Development Activities

Early Stage Products (Phase I)

• Comparative Analysis

AB 329: Daiichi Sankyo Company

• Product Description
• Research and Development
• Product Development Activities

Pre-clinical and Discovery Stage Products

• Comparative Analysis

Q-702: Qurient Co

• Product Description
• Research and Development
• Product Development Activities

Inactive Products

• Comparative Analysis

AXL Kinase Inhibitor Key Companies

AXL Kinase Inhibitor Key Products

AXL Kinase Inhibitor- Unmet Needs

AXL Kinase Inhibitor- Market Drivers and Barriers

AXL Kinase Inhibitor- Future Perspectives and Conclusion

AXL Kinase Inhibitor Analyst Views

AXL Kinase Inhibitor Key Companies

Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/waxump

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900